Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ajay Sood

Child & Adolescent Psychiatry Charleston, SC Medical Doctor

NPI 1881803641 CMS profile 357545

255 King St, Charleston, SC 29401

Open in the dashboard

General payments

$631

44 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ajay Sood of Charleston, SC is reported in the CMS Open Payments database as having received $631 across 44 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 70th percentile of Child & Adolescent Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $94 5
2020 General $36 2
2019 General $502 37

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ajay Sood
  • Child & Adolescent Psychiatry median
  • Middle half of Child & Adolescent Psychiatry
  • National median

In program year 2025, general payments to Ajay Sood were reported at $94. Among 1,601 Child & Adolescent Psychiatry profiles paid that year, the median was $132 and the middle half received between $41 and $474.

Show as a table
Year Ajay Sood Child & Adolescent Psychiatry median Middle half National median
2019 $502 $129 $42–$419 $163
2020 $36 $81 $28–$226 $114
2021 $0 $115 $31–$326 $132
2022 $0 $124 $40–$382 $149
2023 $0 $130 $45–$420 $160
2024 $0 $141 $42–$490 $164
2025 $94 $132 $41–$474 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sunovion Pharmaceuticals Inc. $143 10 payments
  2. Allergan Inc. $135 14 payments
  3. Janssen Pharmaceuticals, Inc $99 6 payments
  4. Alkermes, Inc. $60 3 payments
  5. Neurocrine Biosciences, Inc. $55 4 payments
  6. Indivior Inc. $29 2 payments
  7. Axsome Therapeutics, Inc. $26 1 payment
  8. Vanda Pharmaceuticals Inc. $24 1 payment
  9. Jazz Pharmaceuticals Inc. $22 1 payment
  10. Otsuka America Pharmaceutical, Inc. $21 1 payment
  11. Other $18 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $631 44 payments
Products named General payments · program years 2019–2025
  1. LATUDA $143 10 payments
  2. VRAYLAR $135 14 payments
  3. INVEGA SUSTENNA $83 5 payments
  4. SPRAVATO $62 4 payments
  5. ARISTADA Cns $60 3 payments
  6. ARISTADA Cns $60 3 payments
  7. ARISTADA Cns $60 3 payments
  8. ARISTADA Cns $60 3 payments
  9. ARISTADA INITIO $60 3 payments
  10. INGREZZA $55 4 payments
  11. Other $193 10 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

492

Median for Psychiatry: 574

Drug cost

$19,959

Median for Psychiatry: $27,624

Branded share of claims

26.6%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lamotrigine Er Lamotrigine Brand 13 $6,846
Aripiprazole Generic 27 $6,105
Guanfacine Hcl Er Guanfacine Hcl Brand 23 $2,028
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 46 $1,205
Quetiapine Fumarate Generic 31 $1,106
Duloxetine Hcl Generic 15 $399
Trazodone Hcl Generic 61 $366
Clonazepam Generic 22 $314
Bupropion Xl Bupropion Hcl Brand 38 $264
Hydroxyzine Pamoate Generic 25 $216

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Records

44 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Child & Adolescent Psychiatry in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record